The problem with COVID-19 is so serious because researchers have yet to find an effective treatment that will work right away,media BGR reported. If so, COVID-19 becomes easier to control. Fewer people will die, and those infected may recover faster. Scientists are already working on several promising vaccines and new drugs that could prevent infection and cure disease. But a different team believes that a common drug may prevent new coronaviruses from infecting cells.
We often talk about vaccines and monoclonal antibody drugs. Both drugs can provide protection against infection, as neutralizing antibodies bind to the coronal glycoprotein of the coronavirus, preventing it from infecting cells. But monoclonal antibodies work in patients who are already infected. The vaccine will prevent infection in healthy individuals. Both drugs also provide protection against infection, but vaccines have the upper hand in this game because they provide longer-lasting immunity.
This involves a drug that some people may be familiar with. Heparin is a blood thinner that prevents blood clotting in the blood vessels. A few months ago, researchers found that COVID-19 can cause blood clots, leading to breathing problems, heart attacks and strokes. This is why anticoagulants are used in the treatment of COVID-19.
But researchers from the Rensselaer Institute of Technology found that heparin can actually bind to SARS-CoV-2’s stingy glycoprotein, like neutral antibodies. The drug can be used as a bait to catch the virus and render it ineffective. Once the stinguating glycoprotein is neutralized, the virus will not bind to cells. By blocking this combination of this protein and ACE receptor outside the human cell, heparin prevents the virus from replicating, a process that occurs within the cell.
“This approach can be used as an early intervention to reduce infection in people who have tested positive but have not yet developed symptoms. But we also think it’s part of a larger antiviral strategy,” said study lead author Robert Linhardt, a professor of chemical and chemical biology at the Rensselaer Institute of Technology. “Ultimately, we want a vaccine, but there are many ways to fight the virus, and as we see in HIV, with the right combination of therapies, we can control the disease until we find a vaccine.”
Jonathan Dordick, a professor of chemistry and bioengineering at the same institute, was involved in the same study. Heparin and the virus provide a “special, extremely close combination,” he said. “It’s hundreds of thousands of times closer than a typical antibody-antigen. Once it’s combined, it doesn’t fall off. “
The team tested three versions of heparin, including a low-molecular version of a non-anticoagulant. They used computational modeling to determine where drugs bind to viruses. All experiments have shown that heparin acts as a bait. The video above explains the principle of heparin-SARS-CoV-2 interaction.
But the researchers say more work is needed to prove the safety and efficacy of heparin therapy, and clinical trials are needed in human patients before heparin is used in the way that Lensler scientists suggest. However, this finding is absolutely exciting and noteworthy.